| Date | Title | Description |
| 01.07.2026 | Ipsen to acquire Memo Therapeutics for up to EUR 700 million |
French biopahram company Ipsen and Schlieren-based Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeu... |
| 29.05.2026 | NUCLIDIUM's Series B reaches CHF 105 million with latest extension |
NUCLIDIUM develops radiotheranostics — treatments that combine diagnostic imaging and targeted therapy using structurally similar radioactive molecules. The company's approach links tumor-targeting molecules with copper isotopes: Copper-61... |
| 30.04.2026 | Tacalyx Raises €11 Million To Advance Lead Cancer Therapy Toward The Clinic | Tacalyx, a biotech company focused on the discovery and development of cancer therapies directed at Tumor Associated Carbohydrate Antigens, has secured €11 million in a first closing of its seed extension round to advance its lead clinical ... |
| 28.04.2026 | Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer | SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of ... |
| 24.04.2026 | Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 Billion | Kurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ... |
| 23.04.2026 | Kurma closes €215M Europe-focused fund to spread across 20 biotechs | Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support European startups.
Paris-based Kurma held the first close of Biofund IV in October 2024. At that time, the VC group ... |
| 31.03.2026 | Laigo Bio Secures €17M: SureTACs Platform Targets Cancer, Autoimmune Diseases | Laigo Bio secured €17M seed funding for its SureTACs platform. The biotech pioneers precision membrane protein degradation. Funds will accelerate oncology programs to the clinic. They also advance autoimmune and immunology candidates. The i... |
| 31.03.2026 | Laigo Bio: €17 Million Raised For Biotech Developing SureTACs Precision Protein Degradation Platform | Laigo Bio, a Netherlands-based biotech company developing targeted protein degradation therapies, has completed the final close of its oversubscribed seed financing round, bringing the total raised to €17 million.
The latest tranche include... |
| 23.03.2026 | Laigo Bio Closes €17M Seed Funding | Laigo Bio, an Utrecht, The Netherlands-based biotech company, closed the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m.
This latest investment comes from new co-lead investor Biova... |
| 03.03.2026 | Alveus Therapeutics: $197 Million Series A Raised To Advance Next-Generation Obesity And Metabolic Disease Therapies | Alveus Therapeutics announced the second and final closing of its oversubscribed Series A financing, increasing the total round size to $197 million. The clinical-stage biotechnology company, which is developing next-generation therapies fo... |
| 02.03.2026 | Alveus Therapeutics Raises $37M in Series A Extension Funding | Alveus Therapeutics Inc., a Philadelphia, PA-based clinical-stage biotechnology company, raised $37M in Series A Extension funding.
The latest round included participation from Jeito Capital and Novo Holdings, joining the original Series A ... |
| 13.01.2026 | Alveus Therapeutics Secures $160M Series A for Obesity, Metabolic Disease Innovation | Alveus Therapeutics, a Philadelphia-based biotech company, raised $160M in Series A funding. This significant capital infusion targets advanced therapies for obesity and metabolic diseases. New Rhein, Andera Partners, and Omega Funds led th... |
| 08.01.2026 | Andera Partners co-leads $160 Million Series A round for Alveus to Advance Next-Generation Therapies for Obesity and Metabolic Diseases | Andera Partners, a leading European private equity player, today announced that it is co-leading a $159.8 million Series A round of Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity... |
| 08.01.2026 | Alveus Therapeutics Raises $160M in Series A Financing | Alveus Therapeutics, a Philadelphia, PA-based clinical-stage biotechnology company, raised $160M in Series A funding.
The round was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capi... |
| 04.12.2025 | Targeting the “undruggable”: Laigo Bio secures €11.5 million to advance its SureTAC protein degradation platform | Laigo Bio, an Utrecht-based company pioneering novel and highly differentiated therapies using its proprietary SureTAC precision membrane protein degradation platform, has successfully raised €11.5 million in Seed financing.
The funding rou... |
| 23.10.2025 | Adcytherix: €105 Million Series A Raised For Advancing Antibody-Drug Conjugate Pipeline And Novel Payload Platform | Adcytherix, a biopharmaceutical company pioneering the design and development of novel antibody-drug conjugates (ADCs), announced the completion of a €105 million (US$122 million) Series A financing round. The funding will accelerate the co... |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Wed, Oct 22, 2025 09:20 CET Report this content
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 16.10.2025 | With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | Marseille-based Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Series A financing round to advance its lead candidate and treat high unmet need diseases
... |
| 01.10.2025 | Sunrise Group: $29 Million Raised For Expanding Dreem Health | Sunrise Group, known as a leader in sleep health technology, has announced a funding round of $29 million dedicated to expanding Dreem Health, its innovative digital sleep clinic, to ensure its services reach all 50 states in the U.S. This ... |
| 25.09.2025 | Sunrise Group Raises $29M to Expand Dreem Health and Build the Largest U.S. Sleep Clinic | What You Should Know:
–Sunrise Group, a leader in sleep health technology, today announced a $29 million funding round to expand Dreem Health, its digital sleep clinic, across all 50 states.
– The round was led by Eurazeo, with participatio... |
| 12.07.2025 | Swiss Biotech Secures Major Funding for Advanced Cancer Treatments | Swiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will acce... |
| 11.07.2025 | NUCLIDIUM raises €84M Series B to advance copper-based cancer therapies | NUCLIDIUM, a Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer, has raised €84 million Series B funding.
Leveraging copper is... |
| 10.07.2025 | Nuclidium Raises €84M in Series B Funding | Nuclidium, a Basel, Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, raised €84M in Series B funding
The round was co-led by Angelini Ventures, Kurma Growth Opportuniti... |
| 10.07.2025 | Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer | Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 million.
The round was led b... |
| 10.07.2025 | CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform |
NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy... |
| 07.07.2025 | EvlaBio secures €21 million in seed funding |
Founded with a mission to address high unmet medical need in the cardiorenal field, Swiss German biotech company EvlaBio is developing a targeted treatment for patients suffering from Chronic Kidney Disease (CKD) with limited therapeutic o... |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round.
Nuevocor said in a state... |
| 07.05.2025 | Nuevocor's $45 Million Leap: A New Dawn for Cardiomyopathy Treatment | In the world of biotechnology, every dollar counts. A recent infusion of $45 million into Nuevocor, a Singapore-based company, is more than just a financial boost. It’s a lifeline for patients grappling with cardiomyopathies, particularly t... |
| 06.05.2025 | SG biotech startup Nuevocor raises $45m to help heart failure patients | Singapore-based biotech company Nuevocor has raised $45 million in a Series B funding round to advance the treatment for patients with cardiomyopathies, a form of heart disease that could lead to heart failure, according to a statement on T... |
| 06.05.2025 | Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy | – Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund
– Proceeds will support the Phase 1/2 clinical trial of le... |
| 24.04.2025 | The Rise of Digital Solutions: Transforming Finance and Healthcare | In the fast-paced world of technology, innovation is the lifeblood of progress. Two recent funding rounds highlight this truth, showcasing how digital solutions are reshaping finance and healthcare. Hokodo and Poppins are not just companies... |
| 24.04.2025 | Poppins raises €5M to expand digital therapy for children with dyslexia | Paris startup Poppins has raised €5 million for its digital therapy used in the rehabilitation of dyslexia in children to increase care capacity. This brings its total funding to €20 million.
France has 1.3 million children with dyslexia, w... |
| 10.02.2025 | To encourage at least $220 M in investments in deep tech startups, SEEDS Capital appointed 20 new partners | Twenty new local and international partners have been added by SEEDS Capital (SEEDS), the investment division of Enterprise Singapore (EnterpriseSG), to co-invest in cutting-edge deep tech startups based in Singapore.
According to a stateme... |
| 16.01.2025 | Coave Therapeutics: €32 Million (Series A) Raised For Advancing Genetic Medicines | Coave Therapeutics – a company advancing the future of genetic medicines – announced the raising of €32 million ($33 million) in Series A funding. The funding was co-led by Novo Holdings A/S and Bpifrance, with Invus and UI Investissement p... |
| 10.10.2024 | Kurma Partners: First Closing Of €250 Million Biofund IV | Kurma Partners, an asset manager focused on improving human health, announced that it has raised EUR 140 million, completing the first closing of Biofund IV. By the final closing in 2025, Kurma aims to have raised a total of €250 million in... |
| 04.10.2024 | Igniting Futures: The Power of STEM Exploration Day | In a world where technology reigns supreme, the future hinges on innovation. The Children's Museum of Indianapolis recognized this truth by hosting STEM Exploration Day, a vibrant event designed to inspire young girls to embrace careers in ... |
| 03.10.2024 | European VC firm Kurma closes first $154M of largest planned fund, eyes up to 20 biotech investments | European VC firm Kurma Partners has unveiled its latest biotech fund, with 140 million euros ($154 million) raised so far and three biotech beneficiaries already named.
Kurma plans to raise a total of 250 million euros ($276 million) for th... |
| 03.10.2024 | Kurma Partners Holds First €140M Close of new €250M Biofund IV | Kurma Partners, a Paris, France and Munich, Germany-based international specialist investment firm focused on improving human health, raised EUR 140m, completing the first closing of Biofund IV.
Biofund IV received support from cornerstone ... |
| 03.10.2024 | Kurma Partners raises €140 million first close of new €250 million Biofund IV | Paris-based Kurma Partners, an asset manager focused on improving human health, announced that it has raised €140 million, successfully completing the first closing of Biofund IV. Kurma aims to have raised a total of €250 million in its new... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
Tue, Jul 16, 2024 09:15 CET Report this content
EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 12.07.2024 | Spotlight Medical Secures €6.2M in Seed Funding to Enhance Cancer Treatment Strategies with AI-Powered Prognosis Tests | PARIS–(BUSINESS WIRE)–July 12, 2024–
Spotlight Medical, a pioneering startup developing AI-driven prognosis tests to assist physicians in selecting the most effective treatment for cancer patients, today announced that it has raised €6.2 mi... |
| 07.05.2024 | Memo Therapeutics raises additional CHF20 million |
Schlieren-based Memo Therapeutics is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. MTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat B... |
| 07.09.2023 | Axithra raises € 10 million in Seed funding | Leuven and Ghent (Belgium), 5 September, 2023 – Axithra, a new spin-off of imec and Ghent University, today announced a 10 million euro seed round, securing the first two years of R&D. Axithra develops a technology platform for therapeu... |
| 15.08.2023 | Dutch medtech firm Xeltis secures €12.5M from EIC Fund | Dutch medtech firm Xeltis has secured €12.5 million in funding from the European Innovation Council (EIC) Fund. This brings Xeltis' total amount raised, to date, to €44.5 million. Its investors include DaVita Venture Group, EQT Life Science... |
| 10.03.2023 | Belgium-based Sunrise bags €17M to help people suffering from sleep disorders | Belgium-based Sunrise, a healthtech company that claims to be revolutionising sleep analysis, announced on Thursday, March 9, that it has raised €17M in a fresh round of funding. This funding is in addition to €12M that the startup has alre... |
| 20.10.2022 | DeepUll cierra una ronda serie B de €13 M. liderada por CDTI. Participan Kurma, Alta LS, UI y Axis | 20/10/2022
Nota de prensa
DEEPULL LEVANTA 13 M€ EN UNA RONDA SERIE B PARA AVANZAR EN LA PLATAFORMA DE DETECCIÓN PRECOZ DE LA SEPSIS
DeepUll, una compañía dedicada al diagnóstico médico que desarrolla soluciones diagnósticas económicas y ... |
| 30.06.2022 | French digital clinic Charles.co gets a shot of €7 million to make men’s health solutions more accessible | Paris-based digital clinic entirely dedicated to men’s health issues, Charles.co has brought in €7 million in a seed-stage funding. The funding will allow the startup to expand its offerings and build out its team, which has already support... |
| 30.06.2022 |
Ermium Therapeutics extends its initial €6.3 M funding to €12.3 M to further advance breakthrough auto-immune disease therapeutics | Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partner... |
| 04.02.2022 | Parisian startup revolutionising skin cancer screening raises €5 million to accelerate European rollout | Skin cancers affect over 5 million people worldwide each year and patient prognosis continues to be highly dependent on the timing of diagnosis. Attempting to speed up the diagnosis process is Paris-based medtech company Damae Medical. It h... |
| 20.04.2021 | Synendos Therapeutics raises additional funds in Series A | Synendos is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (... |
| 20.04.2021 | Synendos Therapeutics raises additional funds in Series A | |
| 25.03.2021 | French biotech company Step Pharma raises €35 million in Series B | Step Pharma, a Paris based biotech company, announced on 24th March 2021 that it has raised €35 million in its Series B funding round. The round was led by Sunstone Life Science Ventures and Hadean Ventures, along with participation from Ku... |
| 02.03.2021 | Mesoblast gets a $110M lifeline from SurgCenter Development; uniQure still unsure if gene therapy spurred cancer event | Mesoblast faced rough waters in 2020, but on Monday were thrown a financial lifeline.
The Australian stem cell therapy player has raised $110 million in a private placement, the company announced, offering 60 million share... |
| 12.11.2020 | Synendos Therapeutics secures CHF 20 million | |
| 12.11.2020 | Synendos Therapeutics secures CHF 20 million | Incorporated in April 2019 as a spinoff of the University of Bern and the research consortium, NCCR TransCure, Synendos Therapeutics co-founded by professor Jürg Gertsch and Andrea Chicca (CEO) is focused on introducing a breakthrough appro... |
| 07.07.2020 | DeepUll cierra una ronda de €3,5M liderada por Alta Life Sciences y Kurma. Participan Axis y Sofimac | 07/07/2020
Nota de prensa
DEEPULL CIERRA UNA RONDA DE €3,5 MILLONES LIDERADA POR ALTA LIFE SCIENCES Y KURMA. PARTICIPAN AXIS Y SOFIMAC.
DeepUll fue fundada en 2019 por Jordi Carrera y Rafel Bru quienes también fundaron STAT-Dx, compañía q... |
| 06.09.2019 | Xeltis’ closes €10.5 million Series D financing | |
| 15.11.2017 | Xeltis mit Rekordfinanzierung | |
| 15.11.2017 | Xeltis Closes €45 Million in Series C Financing | |
| 11.04.2016 | STAT Diagnostica cierra una ronda de €25M, acuden GildeHC, Kurma, Boehringer, Ysios Capital, CaixaCR, Axis e Idinvest Partners | 11/04/2016
STAT DIAGNOSTICA CIERRA UNA RONDA DE €25M, ACUDEN GILDE HEALTHCARE, KURMA PARTNERS, BOEHRINGER INGELHEIM, YSIOS CAPITAL, CAIXA CAPITAL RISC, AXIS E IDINVEST PARTNERS.
STAT Diagnostica, compañía especializada en el desarrollo de... |
| 17.12.2015 | Xeltis acquires additional €3M in series B financing | |
| 14.10.2015 | Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M) | Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of €19.4M ($21.7M). Ysios Capital, a Spanish investment fund, led the ... |
| - | French digital clinic Charles.co gets a shot of €7 million to make men’s health solutions more accessible | Paris-based digital clinic entirely dedicated to men’s health issues, Charles.co has brought in €7 million in a seed-stage funding. The funding will allow the startup to expand its offerings and build out its team, which has already support... |
| - | Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment | Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round... |
| - | French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer | Parisian life sciences technology company DNA Script has raised $200 million in a Series C funding round. The company has developed an alternative to traditional DNA synthesis, a proprietary mechanism it calls Enzymatic DNA Synthesis. This ... |
| - | Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases | Paris, France, 4th May 2017 – Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financing round. The r... |
| - | Ganymed Robotics brings home €21 million to launch surgical robots | French startup that develops computer vision software and robotics technologies for orthopaedic surgeons, Ganymed Robotics has raised €21 million in funding. The oversubscribed Series B round was led by Cathay Health, with participation fro... |
| - | Parisian startup revolutionising skin cancer screening raises €5 million to accelerate European rollout | Skin cancers affect over 5 million people worldwide each year and patient prognosis continues to be highly dependent on the timing of diagnosis. Attempting to speed up the diagnosis process is Paris-based medtech company Damae Medical. It h... |
